ILSI-Biomed Israel

LifeBond Raises $20m in a Third Financing Round

LifeBond, a biosurgery device company has completed a $20m fund raising, which was led by Giza Venture Capital and Aurum Ventures. Also participating in the round were existing investors: Pitango Venture Capital and Mr. Robert Taub, GlenRock Israel and The Zitelman Group. LifeBond CEO, Ishay Attar said "LifeBond is marching forward rapidly to provide solutions for major un-met needs in surgery. We welcome the new investors to the company” The start-up company LifeBond, which...

The Israeli Life Science Industry. 2001-2010: A DECADE of GROWTH

Following the big success of ILSI-BioMed Week: some data on Israeli Life Science industry. The Israeli Life Science Industry is young and growing. Of the existing 702 companies, 56% were founded during the last decade. A closer look reveals that a quarter (173 companies) of the Industry was established in the last five years. Figure 1 depicts the trend and growth experienced by the industry in the 2001-2010, period. 306 companies were established prior to 2001, with the oldest one, Teva Pharm...

Some photos from ILSI-Biomed

Photo credit: Ilan Levi www.ilanlevi.com More photos are available at our Facebook page. Tweet

On the opening of the Biomed Israel 2011 week

On the opening of the Biomed Israel 2011 week: President Peres has announced the launch of a brain research international centre in Israel – to be headed by entrepreneur Dr. Rafi Gidron On the opening of the ILSI Biomed Israel 2011 week(Monday, May the 23rd, 2011), President Peres has announced the launch of a new international centre in Israel, set to conduct brain research and to promote the neuro–technology field. Registered as a non–profit association, the centre will be headed (...

Shimon Peres to raise funds for Israeli brain research

President Shimon Peres announced at the 10th ILSI-Biomed Conference 2011 today that he will set up a non-profit organization to support brain research in Israel, which will be headed by Dr. Rafi Gidron. Gidron, a co-founder of Chromatis Networks, which was sold to Lucent for over $4 billion in 2000, is currently involved in volunteer work and invests in cleantech companies through his firm Precede Technologies Ltd. The aim of the proposed NPO will be to shift the emphasis of research in ...

Want to win an iPad2 at ILSI-Biomed?

ILSI-Biomed starts tomorrow! Want to win an iPad2 at ILSI-Biomed? Shizim's iPad2 lottery campaign for Biomed companies: Tell us about your company, and get a chance to win an iPad2 ! Tweet To download the participation form: http://www.lsahome.com/competition/application_2011_iPad.doc

Israel world’s top investor in R&D

srael is the world's top investor in R&D as a proportion of GDP in 2011, according to the World Competitiveness Index of 59 countries by Switzerland's IMD Business School. Israel is ranked 17th in competitiveness overall, the same as in 2010. Israel was also ranked first by IMD in the functioning of central banks. Hong Kong and the US tied for first place in global competitiveness this year, taking over from Singapore, which fell to third place. The Federation of Israeli Chambers of C...

ILSI-Biomed 2011: Israel’s Chief Scientist Reports a 430 million NIS Investment in Life Science Industries and Announces the Field as a Favored Sector

In 2010, the Israeli Chief Scientist approved a total of NIS 430 million in various program budgets. The R&D Committee alone considered 338 support applications from 193 companies for life science projects. 265 projects were approved for State assistance. Statistical reports prepared by the Israeli Chief Scientist office towards the ILSI – Biomed Israel 2011 Week, which will open in Tel Aviv next week (May 23-25, 2011), show that the Chief Scientist helped support life science projects in...

Abbott Diagnostics @ Biomed 2011

Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas: o Evidence of clinical utility o Well characterized antibody development o Preferably, a developed ELISA format o Workable, defendable, global IP position Tweet

Looking for manager – pre clinical development

Looking for manager - pre clinical development • Design and execute pre-clinical studies (in vitro and in vivo) • Manage academic collaborators and CROs, including interactions with project managers, scientists, statisticians and contract departments • Write pre-clinical study protocols, reports and SOP • Report to VP R&D • At least 3 years experience as a scientific project manager in a biotech or pharmaceutical company • Proven experience in leading pre clinical activities includi...